# Hypericin (from Hypericum perforatum)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/hypericin-from-hypericum-perforatum
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-04
**Evidence Score:** 1 / 10
**Category:** Compound
**Also Known As:** Hypericum perforatum extract marker compound, naphthodianthrone pigment, hypericine, St. John's Wort red pigment, ICD inducer hypericin

## Overview

Hypericin is a naphthodianthrone compound that exerts antidepressant, [antiviral](/ingredients/condition/immune-support), and photodynamic anticancer effects through mechanisms including monoamine reuptake inhibition, [reactive oxygen species](/ingredients/condition/antioxidant) (ROS) generation upon light activation, and immunogenic cell death (ICD) induction at the endoplasmic reticulum. In meta-analyses of standardized St. John's Wort extracts—typically standardized to 0.3% hypericin—preparations demonstrated efficacy comparable to tricyclic antidepressants for mild-to-moderate depression with a significantly superior tolerability profile.

## Health Benefits

- **Antidepressant Activity**: Hypericin contributes to the antidepressant effects of St. John's Wort by inhibiting reuptake of [serotonin](/ingredients/condition/mood), dopamine, and norepinephrine, and by modulating sigma receptors; standardized extracts (0.3% hypericin) have shown efficacy in mild-to-moderate major depressive disorder across multiple randomized controlled trials.
- **Photodynamic Anticancer Potential**: Upon light activation, hypericin generates [reactive oxygen species](/ingredients/condition/antioxidant) that trigger apoptosis in tumor cells via endoplasmic reticulum stress pathways, classifying it as the most potent known natural type II immunogenic cell death (ICD) inducer with applications in photodynamic therapy research.
- **Antiviral Properties**: Hypericin demonstrates broad-spectrum antiviral activity in vitro against enveloped viruses including HIV, hepatitis C, and herpes simplex virus, likely through light-dependent and light-independent disruption of viral envelope integrity and interference with viral replication cycles.
- **[Anti-inflammatory](/ingredients/condition/inflammation) Effects**: By modulating cytokine expression and suppressing NF-κB signaling pathways, hypericin reduces pro-inflammatory mediator release, which may contribute both to its antidepressant action and to its broader therapeutic potential in inflammatory conditions.
- **[Neuroprotective](/ingredients/condition/cognitive) Properties**: Emerging preclinical evidence suggests hypericin may upregulate the ABCC1 transporter in brain tissue, facilitating clearance of beta-amyloid plaques associated with Alzheimer's pathology, though human data are currently absent.
- **[Immune Modulation](/ingredients/condition/immune-support) via ICD**: Hypericin-induced immunogenic cell death promotes release of damage-associated molecular patterns (DAMPs) that activate dendritic cells and cytotoxic T lymphocytes, suggesting a potential role in cancer immunotherapy adjunct protocols currently under laboratory investigation.
- **Anxiolytic Support**: Clinical observations in St. John's Wort trials frequently document reductions in anxiety symptoms alongside depression scores, potentially attributable to hypericin's modulation of GABAergic pathways and sigma-1 receptor activity, though isolate-specific anxiolytic trials are lacking.

## Mechanism of Action

Hypericin inhibits the reuptake of monoamine [neurotransmitter](/ingredients/condition/cognitive)s—[serotonin](/ingredients/condition/mood), dopamine, and norepinephrine—by interacting with monoamine transporter proteins, and modulates sigma-1 receptors and adenosine receptors, contributing to its antidepressant and mood-stabilizing effects. Upon exposure to visible or near-infrared light, hypericin undergoes photoexcitation to a triplet state, transferring energy to molecular oxygen to generate singlet oxygen and other [reactive oxygen species](/ingredients/condition/antioxidant) (ROS) that induce lipid peroxidation, [mitochondrial](/ingredients/condition/energy) dysfunction, and endoplasmic reticulum stress-driven apoptosis in target cells—the basis of its photodynamic therapy applications. At higher concentrations, hypericin intercalates into cell membranes, altering permeability and disrupting ion transport, while the ICD mechanism specifically releases calreticulin, HMGB1, and ATP as danger signals that recruit and activate components of the adaptive [immune system](/ingredients/condition/immune-support). Additionally, hypericin appears to upregulate ABCC1 (MRP1) transporter expression in neuronal cells, potentially enhancing efflux of amyloidogenic peptides from the central nervous system, though this pathway has been characterized primarily in preclinical models.

## Clinical Summary

Randomized controlled trials using St. John's Wort extracts standardized to 0.3% hypericin have consistently demonstrated statistically significant reductions in Hamilton Depression Rating Scale (HDRS) scores for mild-to-moderate depression, with effect sizes comparable to tricyclic antidepressants (imipramine, amitriptyline) and selective [serotonin reuptake](/ingredients/condition/mood) inhibitors, while producing substantially fewer side effects. The largest trials, including a 2002 JAMA-published multicenter RCT (n=340), found no significant benefit over placebo for severe major depression, indicating a well-defined efficacy boundary. Photodynamic therapy trials using intravenously administered hypericin for bladder cancer and other malignancies have demonstrated tumor selectivity and preliminary safety in Phase I studies, but Phase II efficacy data with defined response rates remain sparse. Overall clinical confidence in hypericin's antidepressant contribution (within whole extracts) is moderate, while evidence for isolated hypericin in oncology, [antiviral](/ingredients/condition/immune-support), or [neuroprotective](/ingredients/condition/cognitive) applications is preliminary and not yet sufficient to support clinical recommendations.

## Nutritional Profile

Hypericin itself is a pure secondary metabolite (naphthodianthrone class) with no conventional macronutrient value; it is present in H. perforatum aerial parts at approximately 0.03–0.30% dry weight, with elite chemotypes or extracts reaching higher concentrations (up to 90 mg/g in some Hypericum humifusum preparations). The broader phytochemical matrix of St. John's Wort includes hyperforin (2–4% in standardized extracts), flavonoids such as hyperoside, rutin, quercetin, and isoquercitrin (7–12% in flowers), chlorogenic and caffeic phenolic acids, xanthones, and tannins. Hypericin's bioavailability from oral standardized extracts in humans is reported at approximately 14–21%, with peak plasma concentrations reached 3–6 hours post-ingestion and an elimination half-life of roughly 24–48 hours, supporting twice- to three-times-daily dosing; lipophilicity (log P ~4) facilitates membrane penetration but requires formulation optimization for consistent absorption.

## Dosage & Preparation

- **Standardized St. John's Wort Extract (oral capsule/tablet)**: Most clinically studied form standardized to 0.3% hypericin and 3–5% hyperforin; typical dose is 300 mg three times daily (900 mg/day total extract), yielding approximately 0.9 mg hypericin daily.
- **Liquid Tincture (1:5 hydroethanolic extract)**: 2–4 mL three times daily; standardization varies by product; less precise hypericin delivery than standardized capsules.
- **Traditional Herbal Tea Infusion**: 2–3 g dried aerial parts steeped in 150 mL hot water for 10 minutes, consumed 1–3 times daily; hypericin content is lower and highly variable.
- **Photodynamic Therapy (Investigational IV formulation)**: Hypericin administered intravenously at doses ranging from 0.5–2 mg/m² body surface area in clinical research settings prior to light activation; not approved for routine clinical use.
- **Topical Preparations**: Hypericin-containing oils or creams (St. John's Wort macerated oil) used traditionally for wound healing; systemic absorption is minimal but photosensitization risk applies.
- **Standardization Note**: Products should specify both hypericin (0.3%) and hyperforin (3–5%) content; hypericin-only standardization without hyperforin content may inadequately reflect total antidepressant potency.
- **Timing**: Oral extracts are typically taken with meals to reduce gastrointestinal discomfort; patients should avoid direct sunlight for several hours after dosing due to photosensitization risk.

## Safety & Drug Interactions

The most clinically significant adverse effect of hypericin is phototoxic photosensitization—characterized by exaggerated sunburn response, erythema, and in rare cases blistering upon UV light exposure—observed particularly at supratherapeutic doses or with intravenous administration; patients should avoid prolonged sun exposure and use broad-spectrum SPF protection during supplementation. Hypericin-containing St. John's Wort preparations are potent inducers of cytochrome P450 enzymes (primarily CYP3A4 and CYP2C9) and the P-glycoprotein efflux transporter, resulting in clinically significant reductions in plasma levels of numerous medications including oral contraceptives, antiretrovirals (indinavir), warfarin, cyclosporine, digoxin, certain chemotherapy agents, and SSRIs—necessitating thorough medication reconciliation before use. Co-administration with serotonergic medications (SSRIs, SNRIs, MAOIs, tramadol) carries a documented risk of [serotonin](/ingredients/condition/mood) syndrome, a potentially life-threatening condition requiring immediate discontinuation. Hypericin-containing preparations are contraindicated during pregnancy (insufficient safety data, theoretical uterine stimulant activity) and lactation (transfer into breast milk documented), and should be used with caution in individuals with fair skin, bipolar disorder (risk of triggering mania), or ADHD treated with stimulants.

## Scientific Research

The clinical evidence base for hypericin as an isolated compound is limited; most human trial data derives from standardized whole H. perforatum extracts standardized to 0.3% hypericin content, making it difficult to attribute outcomes exclusively to hypericin versus co-occurring hyperforin, flavonoids, or phenolic acids. A 2008 Cochrane systematic review encompassing 29 randomized controlled trials (n > 5,000 participants) found standardized St. John's Wort extracts superior to placebo and equivalent to standard antidepressants for mild-to-moderate depression, with significantly fewer adverse events—though this evidence applies to the whole extract. Preclinical and in vitro studies on isolated hypericin demonstrate robust photodynamic cytotoxicity against multiple cancer cell lines and [antiviral](/ingredients/condition/immune-support) activity, but Phase I/II clinical photodynamic therapy trials using hypericin have been small (typically n < 50) and have faced practical obstacles including the compound's photosensitization side effects. Research into hypericin's [neuroprotective](/ingredients/condition/cognitive) and immunogenic cell death applications remains predominantly at the mechanistic and animal-model stage, representing a significant evidence gap before clinical translation can be recommended.

## Historical & Cultural Context

Hypericum perforatum has been documented in Western herbal medicine for over 2,000 years, with references in ancient Greek texts by Dioscorides and Galen recommending it for nerve pain, wound healing, and melancholy—uses that align remarkably with modern pharmacological findings. The plant's common name, St. John's Wort, derives from its traditional harvest around the feast of St. John the Baptist (June 24), when flowering peaks in Europe, and it was historically draped over doorways and icons as protection against evil spirits and mental illness. In 16th-century Paracelsian medicine, the visible black glands containing hypericin were interpreted through the 'Doctrine of Signatures' as indicating the plant's utility for treating 'black bile' (melancholy), an intuitive association later validated by modern psychopharmacology. By the late 20th century, St. John's Wort became the best-selling herbal antidepressant in Germany and much of Europe, where it is licensed as a prescription phytomedicine, reflecting a rare convergence of folk tradition and regulatory acceptance.

## Synergistic Combinations

Within St. John's Wort extract, hypericin and hyperforin are considered complementary actives—hypericin contributing to monoamine transporter inhibition and sigma receptor modulation while hyperforin provides broader reuptake inhibition and TRPC6 ion channel activation—supporting the rationale for whole-extract formulations over isolated hypericin supplementation. In photodynamic therapy research contexts, hypericin has been studied alongside liposomal delivery systems and photosensitizer-enhancing agents such as tocopherols, which may reduce non-targeted oxidative damage while preserving tumor-directed ROS generation. For general mood support stacks, hypericin-standardized St. John's Wort is sometimes combined with [adaptogen](/ingredients/condition/stress)ic compounds such as Rhodiola rosea (targeting HPA axis regulation) or L-theanine (promoting calm focus), though formal clinical synergy data for these pairings are currently absent.

## Frequently Asked Questions

### What is hypericin and what does it do?

Hypericin is a naturally occurring naphthodianthrone compound found in the dark glandular structures of Hypericum perforatum (St. John's Wort). It contributes to antidepressant effects by inhibiting reuptake of serotonin, dopamine, and norepinephrine, and upon light activation it generates reactive oxygen species capable of inducing apoptosis in cancer cells through immunogenic cell death pathways.

### How much hypericin should I take for depression?

Clinical trials have primarily used standardized St. John's Wort extracts delivering approximately 0.9 mg of hypericin daily, achieved through 300 mg of a 0.3%-standardized extract taken three times per day (900 mg total). Isolated hypericin supplements are not widely available or clinically validated on their own; whole-extract preparations standardized to both 0.3% hypericin and 3–5% hyperforin are considered the evidence-supported form for mild-to-moderate depression.

### Does hypericin cause photosensitivity?

Yes, photosensitization is the most documented adverse effect of hypericin; the compound absorbs UV and visible light and can transfer this energy to skin tissues, causing exaggerated sunburn, erythema, and occasionally blistering in fair-skinned individuals or at high doses. Patients taking hypericin-containing supplements should apply broad-spectrum SPF 30+ sunscreen and minimize prolonged sun or UV lamp exposure throughout the supplementation period.

### Can hypericin interact with medications?

St. John's Wort preparations containing hypericin are among the most clinically significant herbal drug interactors due to potent induction of cytochrome P450 3A4 and P-glycoprotein, which can reduce plasma levels of oral contraceptives, antiretrovirals, warfarin, cyclosporine, and many other drugs by 30–70%. Additionally, combining hypericin with SSRIs, SNRIs, or MAOIs raises the risk of serotonin syndrome, characterized by agitation, hyperthermia, and neuromuscular instability; always inform prescribers before starting supplementation.

### Is hypericin being studied for cancer treatment?

Yes, hypericin is under active preclinical and early clinical investigation as a photosensitizer in photodynamic therapy (PDT) for cancers including bladder, mesothelioma, and skin malignancies, based on its status as the most potent known natural type II immunogenic cell death inducer. Phase I trials have explored intravenous hypericin at doses of 0.5–2 mg/m² with subsequent light activation, demonstrating tumor selectivity, but Phase II efficacy data with defined clinical response rates remain limited and PDT use of hypericin is not currently approved outside research settings.

### Is hypericin safe during pregnancy and breastfeeding?

Hypericin and St. John's Wort extracts are generally not recommended during pregnancy due to limited safety data and potential effects on fetal development. Hypericin may also pass into breast milk and affect nursing infants, so pregnant and breastfeeding women should consult a healthcare provider before use.

### How does hypericin's antidepressant mechanism differ from SSRIs?

Unlike selective serotonin reuptake inhibitors (SSRIs) that target only serotonin reuptake, hypericin inhibits reuptake of serotonin, dopamine, and norepinephrine simultaneously while also modulating sigma receptors, offering a broader mechanism of action. This multi-target approach may explain both its efficacy in mild-to-moderate depression and its different side effect profile compared to conventional SSRIs.

### What clinical evidence supports hypericin's effectiveness for depression?

Multiple randomized controlled trials have demonstrated that standardized St. John's Wort extracts containing 0.3% hypericin are effective for mild-to-moderate major depressive disorder, with efficacy comparable to some conventional antidepressants in several studies. However, evidence is strongest for mild-to-moderate cases, and hypericin is generally considered less effective for severe depression.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*